Drug Profile
Tasquinimod - Active Biotech
Alternative Names: ABR-215050; TASQLatest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator Active Biotech
- Developer Active Biotech; Ipsen; University of Pennsylvania
- Class Amides; Antineoplastics; Fluorinated hydrocarbons; Quinolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Phase I/II Multiple myeloma
- Phase I Myelofibrosis
- Preclinical Myelodysplastic syndromes
- Discontinued Gastric cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cancer
Most Recent Events
- 22 Dec 2023 Active Biotech plans a phase II proof-of-concept trial for Myelofibrosis in Germany and Netherlands in Q3 2024
- 22 Dec 2023 Active Biotech plans a phase II proof-of-concept trial for Myelofibrosis in USA in mid 2024
- 22 Dec 2023 Active Biotech announces intention to file a regulatory application for myelofibrosis